webinar
Oct. 27-28, 2025, Boston, MA, USA - Booth 114.
Read More

MAL-di-EG-Val-Cit-PAB-MMAE

  CAS No.:   Cat No.: BADC-00805 4.5  

MAL-di-EG-Val-Cit-PAB-MMAE is a drug-linker conjugate containing the ADC linker MAL-di-EG-Val-Cit-PAB and the tubulin inhibitor MMAE.

MAL-di-EG-Val-Cit-PAB-MMAE

Structure of

Quality
Assurance

Worldwide
Delivery

24/7 Customer
Support
Category
ADC Cytotoxin with Linker
Molecular Formula
C72H112N12O18
Molecular Weight
1433.73
Shipping
Room temperature

* For research and manufacturing use only. We do not sell to patients.

Size Price Stock Quantity
-- $-- In stock

Looking for different specifications? Click to request a custom quote!

Capabilities & Facilities

Popular Publications Citing BOC Sciences Products
Shipping
Room temperature

MAL-di-EG-Val-Cit-PAB-MMAE is a potent and targeted compound used in the development of antibody-drug conjugates (ADCs) for cancer therapy. The structure includes a malonic acid (MAL) group, a diethylene glycol (di-EG) spacer, a valine-citrulline (Val-Cit) dipeptide, a para-aminobenzyl (PAB) linker, and the cytotoxic drug MMAE (monomethyl auristatin E). The compound is designed to deliver MMAE selectively to cancer cells through the use of a targeting molecule, typically an antibody. The Val-Cit linker provides enzymatic cleavage by specific proteases present in the tumor microenvironment, ensuring that MMAE is released only in targeted cells, minimizing off-target toxicity and enhancing the therapeutic index of the drug. This approach is widely used to improve the specificity and efficacy of cancer treatments.

A key application of MAL-di-EG-Val-Cit-PAB-MMAE is in overcoming the limitations of traditional chemotherapy. MMAE is a highly potent cytotoxic agent that inhibits microtubule dynamics, leading to cell cycle arrest and apoptosis. However, it is too toxic for systemic use. By attaching MMAE to a targeting antibody via the Val-Cit-PAB linker, the drug is delivered specifically to cancer cells, where it is cleaved and activated. This targeted delivery system reduces systemic exposure to MMAE, minimizing harmful side effects like peripheral neuropathy, and significantly improving the safety and efficacy of chemotherapy. The use of this conjugate is particularly beneficial for treating cancers like lymphoma, breast cancer, and non-small cell lung cancer.

MAL-di-EG-Val-Cit-PAB-MMAE also has significant potential in combination therapies. By combining ADCs such as MAL-di-EG-Val-Cit-PAB-MMAE with immune checkpoint inhibitors or other targeted therapies, a synergistic effect can be achieved. The targeted delivery of MMAE can enhance the anti-tumor activity of immune-modulating agents by reducing the tumor burden, which in turn can make the tumor microenvironment more susceptible to immune attack. This combination approach has shown promise in improving the overall therapeutic outcome, particularly in cancers with high mutational burden or resistance to single-agent therapies. This synergistic use holds great potential for enhancing patient response rates and improving long-term survival.

In addition, MAL-di-EG-Val-Cit-PAB-MMAE is useful in the development of personalized medicine strategies. The conjugate can be designed to target specific tumor markers that are unique to an individual patient's cancer, allowing for the delivery of highly tailored treatments. By incorporating biomarkers such as HER2 or CD19 into the targeting antibody, ADCs like MAL-di-EG-Val-Cit-PAB-MMAE can provide precision medicine solutions, improving the effectiveness of therapy and reducing unnecessary side effects. Personalized approaches using such conjugates enable clinicians to select the most effective treatment plan based on the molecular profile of the patient's tumor, leading to better clinical outcomes.

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Related Products

Contact our experts today for pricing and comprehensive details on our ADC offerings.

You May Also Be Interested In

From cytotoxin synthesis to linker design, discover our specialized services that complement your ADC projects.

ADC Payload Development Biological Payload ADC Linker–Payload Conjugation ADC Linker Development Chemical Payload Enzyme Cleavable Linker Cathepsin B Cleavable Linker/Peptide Linker Phosphatase Cleavable Linker β-Glucuronide Linker β-Galactosidase Cleavable Linker

Unlock Deeper ADC Insights

Learn more about payload design, linker strategies, and integrated CDMO support through our curated ADC content.

Maytansine and Its Analogues Linkers - A Crucial Factor in Antibody–Drug Conjugates Cytotoxic Agents Used in Antibody–Drug Conjugates Exatecan Mesylate in ADCs: A New Topo I Inhibitor What is Calicheamicin? What is Monomethyl Auristatin E (MMAE)? What is Monomethyl Auristatin F (MMAF)? What is Pyrrolobenzodiazepine (PBD)? Antiviral Potential of Thapsigargin in COVID-19 Research In-Depth Review of ADC Linkers: Types, Mechanisms, and Research Progress

Explore More ADC Products

Find exactly what your project needs from our expanded range of ADCs, offering flexible options to fit your timelines and goals.

ADC Cytotoxin

Powerful Targeted Cancer Solutions

ADC  Cytotoxin with Linker

Enhanced Stability And Efficacy

ADC Linker

Precise Conjugation For Success

Antibody-Drug  Conjugates (ADCs)

Maximized Therapeutic Performance

Auristatins

Next-Level Tubulin Inhibition

Calicheamicins

High-Impact DNA Targeting

Camptothecins

Advanced Topoisomerase Inhibition

Daunorubicins / Doxorubicins

Trusted Anthracycline Payloads

Duocarmycins

Potent DNA Alkylation Agents

Maytansinoids

Superior Microtubule Disruption

Pyrrolobenzodiazepines

Ultra-Potent DNA Crosslinkers

Traditional Cytotoxic Agents

Proven Chemotherapy Solutions

Cleavable Linker

Precise Intracellular Drug Release

Non-Cleavable Linker

Exceptional Long-Term Stability

Historical Records: DGN549-C | MAL-di-EG-Val-Cit-PAB-MMAE
Send Inquiry
Verification code
Inquiry Basket